2014 Archived Content
Final days to register! Don't miss networking and collaboration opportunities with international mitochondria researchers!
Day 1 | Day 2 | Brochure
Mitochondrial dysfunction has been identified as an important factor in diseases ranging from neurodegenerative conditions (ALS, Alzheimer’s, Parkinson’s Disease), epilepsy, psychiatric illness and autism, to cardiovascular disease, liver/kidney disease, diabetes and cancer. The wide-ranging impact of mitochondria in so many diseases makes them prime targets for therapeutics.
Additionally, medications for many diseases cause unwanted toxicity to the mitochondria. Mitochondrial toxicity is one of the leading causes of attrition in the drug development process, as well as in post-market drug withdrawals. Targeting Mitochondrial Dysfunction & Toxicity (the first conference of its kind in the US) will present the latest research in new targeting pathways, novel therapeutics, and methods to decrease or eliminate mitochondrial toxicity when developing therapeutics for many indications.
- Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania
- Neuropsychopharmacology Laboratory, Mayo Clinic
- Mitochondrial Research, Nestlé Institute of Health Sciences, Switzerland Astellas Research Institute of America LLC
- Muscle Diseases Group, Novartis Institutes for Biomedical Research
- GALLY International Biomedical Research Consulting LLC
- Cell-Based Assays and Mitochondrial Biology, Pfizer R & D
- Pioneer Valley Life Sciences Institute
- Institute of Translational Medicine, The University of Liverpool
- Safety Prediction, Worldwide Medicinal Chemistry, Pfizer, Inc.
- Lilly Research Laboratories
- Elliott-Barnett-Head Breast Cancer Research and Treatment
- Biochemistry and Molecular Biology, Dalhousie University
- University of Arizona
- Metabolic Solutions Development Company
Day 1 | Day 2 | Brochure
7:45-9:00 am Short Course Registration*
Morning Short Course
9:00 – 12:00 pm Imaging Mitochondria: Seeing the Action Up Close and Live
Highly effective methods of imaging mitochondria and their processes have emerged recently. These new methods enhance in vivo examination of the cells and allow for much more detail of these organelles. This short course will explore some of the most innovative and effective methods for seeing into the “cell engines” and visualizing their operations for better understanding of them.
Instructors and Topics:
Automated 3D-Electron Microscopy Presents New Opportunities for Mitochondrial Research and Drug Development Robin Avila, Ph.D., Scientist, Renovo Neural, Inc.
Non-Invasive Imaging of Retinal Mitochondrial Dysfunction in Age-Related Macular Degeneration and Diabetes Victor Elner, M.D., Ph.D., Ravitz Foundation Professor of Ophthalmology and Visual Sciences Professor, Department of Pathology, University of Michigan Kellogg Eye Center
* Separate registration required
If you have questions, please contact:
Elizabeth J. Lamb
Senior Conference Director
Cambridge Healthtech Institute
Ph: 781-247-6259
Email: elamb@healthtech.com